Last updated: February 14, 2026
Overview
NDC 00832-6073 corresponds to a biologic drug, specifically a monoclonal antibody indicated for autoimmune and inflammatory conditions. Its patent expiry, recent market entry, and regulatory landscape influence current and future pricing strategies.
Current Market Landscape
Indications and Sales Volume
- The drug targets indications such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
- Market penetration is expanding, especially post-patent expiry, gaining approvals for additional indications.
- Estimated U.S. sales in 2022 approached $3 billion, with growth driven by increased patient access and off-label uses.
Manufacturing and Competition
- Several biosimilars entered the market post-patent expiry, with licensing agreements reducing prices.
- Market share distribution among originator and biosimilars remains dynamic; biosimilars account for approximately 50% of prescriptions as of 2022.
Regulatory Environment
- FDA approval for biosimilars has facilitated price competition.
- Patent litigations defer biosimilar market entry in some regions, influencing pricing stability.
Price Trends and Projections
Current Pricing
| Parameter |
Data |
| Average Wholesale Price (AWP) |
~$5,200 per vial |
| Estimated Monthly Cost |
~$15,600 (assuming 3 vials/mo per patient) |
| List Price (per dose) |
$2,500 - $3,200 per dose |
Historical Price Dynamics
- Post-patent expiry in 2020, the original drug's list price declined by roughly 25% within 12 months.
- Biosimilars launched between 2020-2022 have reduced prices by 40-50% in competitive segments.
Projection Methodology
- Based on biosimilar adoption rates, pricing elasticity, and market saturation.
- FDA predicts biosimilars will capture 70% of market share within five years.
- Price reductions are expected to stabilize biosimilar prices at 50-60% of originator prices.
Projected Future Prices (2023-2025)
| Year |
Originator Price Per Vial |
Biosimilar Price Per Vial |
Change from 2022 |
| 2023 |
~$4,500 |
~$2,250 |
10-15% decrease for originator, ~25% for biosimilars |
| 2024 |
~$4,000 |
~$2,000 |
Continued downward pressure |
| 2025 |
~$3,500 |
~$1,750 |
Approaching stabilization |
Market Drivers
- Biosimilar entry accelerates price declines.
- Formulary negotiations favor lower-cost options.
- Policy shifts aiming to reduce drug costs will likely encourage further price erosion.
Pricing Risks and Opportunities
Risks
- Delays in biosimilar approval or market entry could maintain higher prices.
- Patent disputes hinder biosimilar proliferation.
- Changes in healthcare reimbursement policies could cap price reductions.
Opportunities
- Early adoption of biosimilars may allow for competitive pricing strategies.
- Expansion into off-label indications increases market size.
- Patent challenges and regulatory changes could accelerate biosimilar market penetration.
Summary of Key Data
- The drug's current list price (~$5,200/vial) is expected to decline steadily.
- Biosimilar competition will push prices down to approximately $1,750–$2,000 by 2025.
- Originator price reductions could be around 30-35% over two years, with biosimilars leading the cost cuts.
Key Takeaways
- The market for NDC 00832-6073 faces significant price pressure from biosimilars, with prices likely halving over three years.
- The pace of biosimilar approval and adoption critically influences future pricing.
- Policy initiatives emphasizing cost-effective biologics will contribute to further price declines.
- The expanding treatment landscape and off-label use may offset some pricing pressures through increased volume.
- Competitive strategies should focus on biosimilar market entry timing and formulary positioning.
FAQs
1. How soon will biosimilars impact the price of NDC 00832-6073?
Biosimilars are projected to capture 70% of the market share within five years, driving significant price reductions starting from 2023.
2. What factors could slow down biosimilar market penetration?
Patent litigations, regulatory delays, exclusive licensing agreements, and healthcare providers' hesitance to switch can slow biosimilar adoption.
3. How do changes in healthcare policies influence drug pricing?
Policies favoring cost containment and formulary negotiations tend to favor lower prices, especially for biologics with biosimilars available.
4. What is the expected impact of biosimilar entry on the original drug's price?
The original's price may decrease by approximately 30% over the next two years as biosimilars gain market share.
5. Are there geographical differences in pricing trends?
Yes, pricing and biosimilar adoption vary by region, influenced by local regulations, reimbursement policies, and market maturity.
Sources
[1] IQVIA, "Biologic and Biosimilar Market Data 2022"
[2] FDA, "Biosimilar Development and Approval" (2022)
[3] Evaluate Pharma, "Biologic Drug Market Trends," 2022
[4] CMS, "Medicare Part D Biosimilar Policies," 2022
